Kyverna Therapeutics, Inc. (KYTX) Ownership
KYTX ownership summary
as of October 18, 2026- Institutions
- 78.7% of shares outstanding
- Insiders
- 6.98% of shares outstanding
- Shares outstanding
- 61.8M
- Float
- 39.7M shares available to trade
- Short interest
- 18.26% 9.6M shares short
- Days to cover
- 10.19 short interest up 9.7% vs prior month
- Institutions 78.74%
- Insiders 6.98%
- Other investors 14.28%
KYTX top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | GordonMD Global Investments LP | 6.86% | 4.2M | $24.1M | — | June 30, 2026 |
| 2 | BlackRock Inc | 5.07% | 3.1M | $17.8M | +2.3M (+257.4%) | June 30, 2026 |
| 3 | Bain Capital Life Sciences Investors, LLC | 4.67% | 2.9M | $16.4M | −225,000 (−7.2%) | June 30, 2026 |
| 4 | AIGH Capital Management, LLC | 4.52% | 2.8M | $15.9M | +795,797 (+39.8%) | June 30, 2026 |
| 5 | Deerfield Management Co | 3.23% | 2.0M | $11.3M | — | June 30, 2026 |
| 6 | Vanguard Capital Management, LLC | 3.07% | 1.9M | $10.8M | +114,109 (+6.4%) | June 30, 2026 |
| 7 | T. Rowe Price Associates, Inc. | 1.92% | 1.2M | $6.7M | −369,264 (−23.7%) | June 30, 2026 |
| 8 | Geode Capital Management, LLC | 1.70% | 1.0M | $6.0M | +625,604 (+147.6%) | June 30, 2026 |
| 9 | INSIGHT HOLDINGS GROUP, LLC | 1.60% | 989K | $5.6M | — | June 30, 2026 |
| 10 | Morgan Stanley - Brokerage Accounts | 1.59% | 982K | $5.6M | +5,018 (+0.5%) | June 30, 2026 |
| 11 | State Street Corp | 1.59% | 982K | $5.6M | +843,933 (+610.2%) | June 30, 2026 |
| 12 | Propel Bio Management LLC | 1.43% | 883K | $5.0M | +238,777 (+37.1%) | June 30, 2026 |
| 13 | Woodline Partners LP | 1.37% | 845K | $4.8M | — | June 30, 2026 |
| 14 | Millennium Management LLC | 1.03% | 640K | $3.6M | −365,728 (−36.4%) | June 30, 2026 |
| 15 | MBB PUBLIC MARKETS I LLC | 0.99% | 614K | $3.5M | — | June 30, 2026 |
| 16 | Adage Capital Partners Gp LLC | 0.81% | 500K | $2.8M | — | June 30, 2026 |
| 17 | D. E. Shaw & Co LP | 0.76% | 469K | $2.7M | −252,235 (−35.0%) | June 30, 2026 |
| 18 | Wells Fargo & Co | 0.60% | 373K | $2.1M | +258,610 (+226.1%) | June 30, 2026 |
| 19 | UBS Group AG | 0.59% | 366K | $2.1M | −84,176 (−18.7%) | June 30, 2026 |
| 20 | The Goldman Sachs Group Inc | 0.54% | 335K | $1.9M | +122,320 (+57.5%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 9 holders added 5.3M shares and 5 cut 1.3M.
KYTX top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | MEDICAL BioHealth EUR Acc | 2.85% | 1.8M | $10.0M | +373 (+0.0%) | August 31, 2026 |
| 2 | Vanguard MStar Total Stk Mkt Idx Invest | 2.27% | 1.4M | $8.0M | — | August 31, 2026 |
| 3 | iShares Russell 2000 ETF | 1.79% | 1.1M | $6.3M | −12,800 (−1.1%) | September 30, 2026 |
| 4 | T. Rowe Price Health Sciences | 1.39% | 857K | $4.9M | — | August 31, 2026 |
| 5 | Fidelity Enhanced Small Cap Core ETF | 0.79% | 488K | $2.8M | +1,023 (+0.2%) | September 30, 2026 |
| 6 | Fidelity Small Cap Index | 0.74% | 458K | $2.6M | +2,641 (+0.6%) | July 31, 2026 |
| 7 | apo Medical Opportunities R | 0.60% | 369K | $2.1M | — | August 31, 2026 |
| 8 | iShares Russell 2000 Value ETF | 0.57% | 354K | $2.0M | +536 (+0.2%) | September 30, 2026 |
| 9 | iShares Biotechnology ETF | 0.48% | 294K | $1.7M | −2,224 (−0.8%) | September 30, 2026 |
| 10 | Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 0.42% | 259K | $1.5M | — | September 30, 2026 |
| 11 | Vanguard Russell 2000 ETF | 0.39% | 241K | $1.4M | +6,085 (+2.6%) | August 31, 2026 |
| 12 | Schwab US Small-Cap ETF™ | 0.31% | 191K | $1.1M | +126 (+0.1%) | September 30, 2026 |
| 13 | Simplify Propel Opportunities ETF | 0.30% | 183K | $1.0M | — | September 30, 2026 |
| 14 | Nuveen Equity Index R6 | 0.29% | 178K | $1.0M | — | August 31, 2026 |
| 15 | iShares Micro-Cap ETF | 0.21% | 132K | $750,974 | −913 (−0.7%) | September 30, 2026 |
| 16 | RIM Global Bioscience EUR | 0.21% | 130K | $735,955 | — | June 30, 2026 |
| 17 | Fidelity Extended Market Index | 0.19% | 116K | $659,325 | −68,709 (−37.1%) | August 31, 2026 |
| 18 | Bridgeway Ultra-Small Company | 0.18% | 112K | $635,040 | — | June 30, 2026 |
| 19 | WesMark Small Company Fund | 0.18% | 110K | $625,401 | — | June 30, 2026 |
| 20 | Galileo - Biotech Innovation Fund S USD | 0.18% | 110K | $623,700 | — | March 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
KYTX insider transactions
latest 3| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-18 | Beth C Seidenberg | Buy | $7.50 | 133,333 | $999,998 |
| 2025-12-18 | Biopartners Opportuni Westlake | Buy | $7.50 | 133,333 | $999,998 |
| 2025-12-15 | Karen Marie Walker | Sell | $12.20 | 23,998 | $292,776 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
KYTX shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns KYTX
Institutional investors own 78.7% of Kyverna Therapeutics's shares and insiders 6.98%. The largest holder is GordonMD Global Investments LP with 6.86% of the shares (4.2M), as of June 30, 2026. Among the top 20 institutions, 9 added shares and 5 reduced their stake in the latest filings. Short interest is 18.26% of the float, or 10.19 days of average trading volume. The share count rose 9.4% since 2022.
Related: KYTX analyst forecast, KYTX key metrics. See the KYTX stock overview for the latest quote and news.
KYTX ownership FAQ
Who owns the most Kyverna Therapeutics stock?
The largest shareholders of Kyverna Therapeutics are GordonMD Global Investments LP (6.86%), BlackRock Inc (5.07%), Bain Capital Life Sciences Investors, LLC (4.67%), AIGH Capital Management, LLC (4.52%), Deerfield Management Co (3.23%).
What percentage of Kyverna Therapeutics is owned by institutions?
Institutions hold 78.7% of Kyverna Therapeutics's shares outstanding; insiders hold 6.98%.
Which funds own Kyverna Therapeutics?
The largest fund holders of Kyverna Therapeutics are MEDICAL BioHealth EUR Acc (2.85%), Vanguard MStar Total Stk Mkt Idx Invest (2.27%), iShares Russell 2000 ETF (1.79%), T. Rowe Price Health Sciences (1.39%), Fidelity Enhanced Small Cap Core ETF (0.79%).
What is Kyverna Therapeutics's short interest?
9.6M shares of Kyverna Therapeutics were sold short, 18.26% of the float; at the average daily volume it would take 10.19 days to cover.
Are insiders buying or selling Kyverna Therapeutics?
Of the latest 3 reported insider transactions in Kyverna Therapeutics (since December 15, 2025), 2 were purchases and 1 were sales.
How many shares of Kyverna Therapeutics are outstanding?
Kyverna Therapeutics has 61.8M shares outstanding, of which 39.7M are in the public float.